Kaiser Permanente expanding its Atlanta presence

Kaiser Permanente has announced plans to open a new IT campus in Atlanta that create approximately 900 new IT jobs by 2019.

The new jobs will bring Kaiser Permanente’s total presence in Georgia to more than 4,000 employees and physicians. Kaiser is Georgia’s largest not-for-profit health plan serving nearly 280,000 members.

“We’re thrilled that Kaiser Permanente is bringing new jobs to Atlanta," said Atlanta Mayor Kasim Reed. "Kaiser Permanente recognizes the Atlanta area as the ‘silicon peach’ — one of the fastest growing regions for information technology work.”

Kaiser Permanente HealthConnect®, the organization’s EHR, is the largest non-governmental medical record system in the world. KP HealthConnect enables Kaiser Permanente’s 17,000 physicians to electronically access the medical records of its approximately 9.6 million members nationwide. Through its personal health records system My Health Manager, members can email their doctors, schedule appointments, refill prescriptions, and view lab results from their computers and mobile devices. In 2014 Kaiser Permanente members viewed more than 78 million test results, sent more than 20 million emails to their physicians, filled 17 million prescriptions, and booked 4 million appointments through My Health Manager.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.